non-small cell lung cancer
Conditions
Interventions
experimental group:low-dose nab-paclitaxel plus tislelizumab
Sponsors
Changzhou Second People's Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 82 Years
Inclusion criteria
Inclusion criteria: 1. Participants aged >=65 years; 2. Participants understand the research steps and contents, and sign the written informed consent voluntarily; 3. Patients with non-small cell lung cancer confirmed by histopathology and / or cytology; 4. Patients have at least one measurable lesion according to RECIST 1.1 standard; 5. Patients with expected survival >= 3 months; 6. Patients failed in one or more lines treatment with platinum-based chemotherapy or targeted therapy. Patients with?epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) variations were eligible to participate if they had disease progression with at least 1 approved corresponding inhibitor; 7. Patients without use of PD-1 / PD-L1 inhibitors before; 8. Patients with less severe hematopoiesis, heart, lung, liver and kidney dysfunction and immune deficiency; 9. Neutrophils >=1.5x10^9/L; hemoglobin >= 9g/dl; platelets >=100 x 10^9/L; total bilirubin <=1.5 ULN; ast (SGOT) and ALT (SGPT) <= 2.5 ULN; creatinine <=1.5 ULN.
Exclusion criteria
Exclusion criteria: 1. Patients with any active autoimmune disease or a history of autoimmune disease (such as interstitial Pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (which can be included after hormone replacement therapy is effective), and have a history of using immunosuppressant within 28 days, but for the treatment of radiotherapy and chemotherapy except for toxic hormones; 2. Patients with more than level 2 adverse events not recovered (i.e. level 1 or baseline level) caused by the treatment received before the first use of the study drug. According to the judgment of researchers, adverse events (such as neurotoxicity) that are difficult to recover quickly can be included in the group; 3. Those patients who were judged by the researchers to have non infectious pneumonia caused by previous radiotherapy and chemotherapy; 4. Patients who are known to be allergic to macromolecular protein preparations, or to any of the components of Tislelizumab and its preparations; 5. Patients with uncontrolled clinical symptoms or diseases of the heart, such as: (1) NYHA grade II or above heart failure; (2) Unstable angina; (3) Myocardial infarction occurred within one year; (4) Patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention; 6. Patients with congenital or acquired immune deficiency (such as HIV infected patients), active hepatitis B (HBV-DNA >=104 copies / ml) or hepatitis C (HCV antibody positive, and HCV-RNA higher than the detection limit of the analysis method) or active tuberculosis; 7. Patients with active infection or fever with unknown cause more than 38.5 degrees within 2 weeks before randomization (according to the judgment of the researcher, the fever of the subject due to tumor can be included in group); 8. According to the researcher's judgment, there are other factors that may cause him / her to be forced to terminate the study midway, such as other serious diseases (including mental diseases) requiring combined treatment, family or social factors, which may affect the safety of the subject or the collection of experimental data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival;safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;disease control rate;overall survival; | — |
Countries
China
Contacts
Public ContactJiang Hua
Changzhou Second People's Hospital
Outcome results
None listed